Home
KPRX
KPRX News

Latest Kiora Pharmaceuticals Inc. (KPRX) News on April 24, 2025

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Newsfile

20 days ago

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Newsfile

a month ago

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Newsfile

a month ago

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Newsfile

2 months ago

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Newsfile

2 months ago

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative

Simply Wall St.

5 months ago

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Newsfile

6 months ago

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

TipRanks

6 months ago

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Newsfile

6 months ago

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Newsfile

7 months ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 09/13/2024

MT Newswires

8 months ago

Kiora Pharmaceuticals Shares Rise After Q2 Loss Narrows

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Newsfile

8 months ago

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Newsfile

9 months ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Newsfile

9 months ago

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Newsfile

9 months ago

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Newsfile

10 months ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Newsfile

10 months ago

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?

Zacks

10 months ago

Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%

Simply Wall St.

10 months ago

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

10 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

10 months ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

10 months ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

10 months ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

10 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Simply Wall St.

10 months ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Simply Wall St.

10 months ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

AFP

10 months ago

Seoul resumes loudspeaker propaganda against North

Better AI Stock: Palantir vs. Snowflake

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BigBear.ai Stock: Buy, Sell, or Hold?

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

a year ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

PR Newswire

a year ago

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

3 Major Product Releases at 3Shape Discover Event

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

GlobeNewswire

a year ago

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Simply Wall St.

a year ago

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Business Wire

a year ago

Net Asset Value(s)

Irish, Czechs hold EU vote after Dutch far-right gains

AFP

a year ago

Irish, Czechs hold EU vote after Dutch far-right gains

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

Motley Fool

a year ago

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

GlobeNewswire

a year ago

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024

Newsfile

a year ago

Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Newsfile

a year ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Newsfile

a year ago

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

Newsfile

a year ago

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Newsfile

a year ago

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Newsfile

a year ago

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Newsfile

a year ago

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Newsfile

a year ago

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Newsfile

a year ago

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Newsfile

a year ago

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Newsfile

a year ago

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Newsfile

a year ago

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Jet.AI Launches Reroute AI Software to Intelligently Repurpose Empty Flight Legs for 5,000+ U.S. Part 135 Charter Operators

GlobeNewswire

a year ago

Jet.AI Launches Reroute AI Software to Intelligently Repurpose Empty Flight Legs for 5,000+ U.S. Part 135 Charter Operators

Bionomics Provides a Review of 2023 and of 2024 Plans

GlobeNewswire

a year ago

Bionomics Provides a Review of 2023 and of 2024 Plans

Gauzy, Research Frontiers and LG Display Reveal at 2024 CES Show How to Make Transparent OLEDs Even Better by Integrating Research Frontiers SPD-Smart Film Technology

GlobeNewswire

a year ago

Gauzy, Research Frontiers and LG Display Reveal at 2024 CES Show How to Make Transparent OLEDs Even Better by Integrating Research Frontiers SPD-Smart Film Technology

SOL Global Changes Auditor and Provides Corporate Update

Newsfile

a year ago

SOL Global Changes Auditor and Provides Corporate Update

Trust Stamp announces a patent filing for a groundbreaking AI-powered facial recognition technology

GlobeNewswire

a year ago

Trust Stamp announces a patent filing for a groundbreaking AI-powered facial recognition technology

Business Wire

a year ago

Marygold Named "Most Innovative" by Best In Biz Awards Program for Recently Introduced Mobile Fintech App

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

GlobeNewswire

a year ago

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

10 Supplements for Longevity and Antiaging: Expert Recommendations

Insider Monkey

a year ago

10 Supplements for Longevity and Antiaging: Expert Recommendations

HedoniaUSA Inc. Selects Dolphin Entertainment As Its Communications Agency of Record

PR Newswire

a year ago

HedoniaUSA Inc. Selects Dolphin Entertainment As Its Communications Agency of Record

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

GlobeNewswire

a year ago

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Final Results of Rights Offering

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Preliminary Results of Rights Offering

Paramount Gold Announces The Voting Results Of Its 2023 Annual General Meeting

GlobeNewswire

a year ago

Paramount Gold Announces The Voting Results Of Its 2023 Annual General Meeting

Revolutionizing The Carbon Credit Industry: Introducing The Spectaire Carbon Offset Portal

GlobeNewswire

a year ago

Revolutionizing The Carbon Credit Industry: Introducing The Spectaire Carbon Offset Portal

Shareholders in SuRo Capital (NASDAQ:SSSS) are in the red if they invested three years ago

Simply Wall St.

a year ago

Shareholders in SuRo Capital (NASDAQ:SSSS) are in the red if they invested three years ago

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Extends Expiration Date of Non-Transferable Rights Offering; Reinstates Quarterly Distribution; Revises Self-Tender Policy; Extends Management Fee Waiver; and Reports Results of Annual Stockholder Meeting

Associated Press Finance

a year ago

Gulf Resources: Q3 Earnings Snapshot

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

GlobeNewswire

a year ago

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering

GlobeNewswire

a year ago

authID Inc. Announces Pricing of Approximately $9.4 Million Registered Direct Offering

News Direct

a year ago

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

Zacks Small Cap Research

a year ago

SDOT: Sadot Group reports 3rd quarter operating results which showed continued high levels of revenue generation in the core agri-foods subsidiary.

Safe Harbor Originates $3 Million First Lien Secured Loan for Multi-tenant Cannabis Industrial Building in California

GlobeNewswire

a year ago

Safe Harbor Originates $3 Million First Lien Secured Loan for Multi-tenant Cannabis Industrial Building in California

The Market Doesn't Like What It Sees From Dragonfly Energy Holdings Corp.'s (NASDAQ:DFLI) Revenues Yet As Shares Tumble 60%

Simply Wall St.

a year ago

The Market Doesn't Like What It Sees From Dragonfly Energy Holdings Corp.'s (NASDAQ:DFLI) Revenues Yet As Shares Tumble 60%

First US Bancshares, Inc. Announces Extension of Share Repurchase Program

PR Newswire

a year ago

First US Bancshares, Inc. Announces Extension of Share Repurchase Program

Movella Announces Delayed 10-Q Filing

GlobeNewswire

a year ago

Movella Announces Delayed 10-Q Filing

Sadot Group Inc. Reports Third Quarter 2023 Results

ACCESSWIRE

a year ago

Sadot Group Inc. Reports Third Quarter 2023 Results

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

PR Newswire

a year ago

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

Business Wire

a year ago

The Marygold Companies Reports Financial Results for 2024 First Fiscal Quarter

Movella Holdings Delays Third Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire

a year ago

Movella Holdings Delays Third Quarter 2023 Financial Results Conference Call and Webcast

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Newsfile

a year ago

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock

GlobeNewswire

a year ago

DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock

Bridger Aerospace Announces Schedule for its Third Quarter 2023 Earnings Release and Conference Call

GlobeNewswire

a year ago

Bridger Aerospace Announces Schedule for its Third Quarter 2023 Earnings Release and Conference Call

Kaival Brands Leads the Way in Compliance as FDA Ramps Up Enforcement of Illicit Vape Products

GlobeNewswire

a year ago

Kaival Brands Leads the Way in Compliance as FDA Ramps Up Enforcement of Illicit Vape Products

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GlobeNewswire

a year ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GlobeNewswire

a year ago

CORRECTION - The Herzfeld Caribbean Basin Fund, Inc. Announces Estimated Subscription Price for Rights Offering

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Estimated Subscription Price for Rights Offering

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire

a year ago

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Share on Social Networks: